The interaction of methamphetamine with human immunodeficiency virus (HIV), the aetiologic agent of Acquired Immune Deficiency Syndrome (AIDS), has not been thoroughly investigated. However, increasingly, a larger proportion of HIV infected individuals acquire the virus through methamphetamine use or are exposed to this drug during their disease course. In certain populations, there is a convergence of methamphetamine use and HIV-1 infection; yet our understanding of the potential effects that simultaneous exposure to these two agents have on disease progression is extremely limited. Studying the interactions between methamphetamine and lentivirus in people is difficult. To thoroughly understand methamphetamine's effects on lentivirus disease progression, an animal model that is both clinically relevant and easily manipulated is essential. In this report, we identified potential problems with methamphetamine abuse in individuals with a concurrent HIV-1 infection, described the Feline Immunodeficiency Virus (FIV)/cat model for HIV-1, and reported our early findings using this modelling system to study the interaction of methamphetamine and lentivirus infections.
Abbruzzese G, Rizzo F, DalL'Agata D, Morandi N, Favale E (1990) Generalized dystonia with bilateral striatal computedtomographic lucencies in a patient with human immunodeficiency virus infection. Eur Neurol30: 271–273
2.
Adler A, Lukas S E (1996) Proceedings of the National Consensus Meeting on the use, abuse and sequelae of abuse of methamphetamine with implications for prevention, treatment and research on problems of drug dependence. DHHS, SMA 96–8013, San Juan, Puerto Rico, pp. 1–38
3.
Ali S F, Newport R R, Holson W, Slikker W Jr, Bowyer J F (1995) Low environmental temperatures or pharmacologic agents that produce hypothermia decrease methamphetamine neurotoxicity in mice. Ann NY Acad Sci765: 338-338
4.
Baker W W, Zivanovic D, Malseed R T (1976) Tremorogenic effects of intracaudate d-amphetamine and their suppression by dopamine. Arch Int Pharmacodyn Ther223: 271–281
5.
Balster R L, Kilbey M M, Ellinwood E H Jr (1976) Methamphetamine self-administration in the cat. Psychopharmacologia46: 229–233
6.
Barks J D, Sun R, Malinak C, Silverstein F S (1995) gp120, an HIV-1 protein, increases susceptibility to hypoglycemic and ischemic brain injury in perinatal rats. Exp Neurol132: 123–133
7.
Broening H W, Pu C, Vorhees C V (1997) Methamphetamine selectively damages dopaminergic innervation to the nucleus accumbens core while sparing the shell. Synapse27: 153–160
8.
Bukrinsky M I, Nottet H S, Schmidtmayerova H, Dubrovsky L, Flanagan C R, Mullins M E, Lipton S A, Gendelman H E (1995) Regulation of nitric oxide synthase activity in human immunodeficiency virus type 1 (HIV-1)-infected monocytes: implications for HIV-associated neurological disease. J Exp Med181: 735–745
9.
Cadet J L, Ali S, Epstein C (1994) Involvement of oxygen-based radicals in methamphetamine-induced neurotoxicity: evidence from the use of CuZnSOD transgenic mice. Ann NY Acad Sci738: 388–391
10.
Callahan B, Yuan J, Stover G, Hatzidimitriou G, Ricaurte G (1998) Effects of 2-deoxy-D-glucose on methamphetamine-induced dopamine and serotonin neurotoxicity. J Neurochem70: 190–197
11.
Cappon G D, Morford L L, Vorhees C V (1997) Ontogeny of methamphetamine-induced neurotoxicity and associated hyperthermic response. Brain Res Dev Brain Res103: 155–162
12.
Chao C C, Hu S, Peterson P K (1996) Glia: the not so innocent bystanders. J Neurovirol2: 234–239
13.
Choi D W (1992) Excitotoxic cell death. J Neurobiol23: 1261–1276
14.
Commins D L, Vosmer G, Virus R M, Woolverton W L, Schuster C R, Seiden L S (1987) Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther241: 338–345
15.
Connor T J, McNamara M G, Finn D, Currid A, O'Malley M, Redmond A M, Kelly J P, Leonard B E (1998) Acute 3, 4-methylenedioxymethamphetamine (MDMA) administration produces a rapid and sustained suppression of immune function in the rat [in process citation]. Immunopharmacology38: 253–260
16.
Cubells J F, Rayport S, Rajendran G, Sulzer D (1994) Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J Neurosci14: 2260–2271
17.
Dankova J, Boucher R, Poirier L J (1977) Effects of 1694 and other dopaminergic agents on circling behavior. Eur J Pharmacol42: 113–121
18.
Davis J L, Clements J E (1989) Characterization of a cDNA clone encoding the visna virus transactivating protein. Proc Natl Acad Sci USA86: 414–418
19.
Dawson V L, Dawson T M, Uhl G R, Snyder S H (1993) Human immunodeficiency virus type 1 coat protein neurotoxicity mediated by nitric oxide in primary cortical cultures. Proc Natl Acad Sci USA90: 3256–3259
20.
Dewhurst S, Gelbard H A, Fine S M (1996) Neuropathogenesis of AIDS. Mol Med Today2: 16–23
21.
Diop A G, Lesort M, Esclaire F, Sindou P, Couratier P, Hugon J (1994) Tetrodotoxin blocks HIV coat protein (gp120) toxicity in primary neuronal cultures. Neurosci Lett165: 187–190
22.
Dreyer E B, Kaiser P K, Offermann J T, Lipton S A (1990) HIV-1 coat protein neurotoxicity prevented by calcium channel antagonists [see comments]. Science248: 364–367
23.
Ellinwood E H Jr, Escalante O (1970) Behavior and histopathological findings during chronic methedrine intoxication. Biol Psychiatry2: 27–39
24.
Emori K, Minabe Y, Tanii Y, Kurachi M (1991) Effects of chronic treatment with haloperidol and methamphetamine on hippocampal kindled seizures in the cat. Epilepsy Res8: 213–219
25.
Escalante O D, Ellinwood E H Jr (1970) Central nervous system cytopathological changes in cats with chronic methedrine intoxication. Brain Res21: 151–155
26.
Everall I, Luthert P, Lantos P (1993) A review of neuronal damage in human immunodeficiency virus infection: its assessment, possible mechanism and relationship to dementia. J Neuropathol Exp Neurol52: 561–566
27.
Everall I P, Hudson L, Kerwin R W (1997) Decreased absolute levels of ascorbic acid and unaltered vasoactive intestinal polypeptide receptor binding in the frontal cortex in acquired immunodeficiency syndrome. Neurosci Lett224: 119–122
28.
Farfel G M, Seiden L S (1995) Role of hypothermia in the mechanism of protection against serotonergic toxicity. II. Experiments with methamphetamine, p-chloroamphetamine, fenfluramine, dizocilpine and dextromethorphan. J Pharmacol Exp Ther272: 868–875
29.
Frosch D, Shoptaw S, Huber A, Rawson R A, Ling W (1996) Sexual HIV risk among gay and bisexual male methamphetamine abusers. J Subst Abuse Treat13: 483–486
30.
Fujii Y, Ishii Y, Suzuki T, Murayama S (1979) Neuropharmacological studies on tolperisone hydrochloride. Nippon Yakurigaku Zasshi75: 655–668
31.
Gendelman H E, Genis P, Jett M, Zhai Q H, Nottet H S (1994a) An experimental model system for HIV-1-induced brain injury. Adv Neuroimmunol4: 189–193
32.
Gendelman H E, Lipton S A, Tardieu M, Bukrinsky M I, Nottet H S (1994b) The neuropathogenesis of HIV-1 infection. J Leukoc Biol56: 389–398
33.
Genis P, Jett M, Bernton E W, Boyle T, Gelbard H A, Dzenko K, Keane R W, Resnick L, Mizrachi Y, Volsky D J, et al. (1992) Cytokines and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophage–astroglia interactions: implications for the neuropathogenesis of HIV disease. J Exp Med176: 1703–1718
34.
Giulian D, Yu J, Li X, Tom D, Li J, Wendt E, Lin S N, Schwarcz R, Noonan C (1996) Study of receptor-mediated neurotoxins released by HIV-1-infected mononuclear phagocytes found in human brain. J Neurosci16: 3139–3153
35.
Grimaldi L M, Martino G V, Franciotta D M, Brustia R, Castagna A, Pristera R, Lazzarin A (1991) Elevated alpha-tumor necrosis factor levels in spinal fluid from HIV-1-infected patients with central nervous system involvement [see comments]. Ann Neurol29: 21–25
36.
Gruol D L, Yu N, Parsons K L, Billaud J N, Elder J H, Phillips T R (1998) Neurotoxic effects of feline immunodeficiency virus, FIVPPR. J NeuroVirol, in press
37.
Guy B, Geist M, Dott K, Spehner D, Kieny M P, Lecocq J P (1991) A specific inhibitor of cysteine proteases impairs a Vif-dependent modification of human immunodeficiency virus type 1 Env protein. J Virol65: 1325–1331
38.
Hayman M, Arbuthnott G, Harkiss G, Brace H, Filippi P, Philippon V, Thomson D, Vigne R, Wright A (1993) Neurotoxicity of peptide analogues of the transactivating protein tat from Maedi–Visna virus and human immunodeficiency virus. Neuroscience53: 1–6
39.
Heaton R K, Grant I, Butters N, White D A, Kirson D, Atkinson J H, McCutchan J A, Taylor M J, Kelly M D, Ellis R J et al.(1995) The HNRC 500 – neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc1: 231–251
40.
Hirata H, Ladenheim B, Rothman R B, Epstein C, Cadet J L (1995) Methamphetamine-induced serotonin neurotoxicity is mediated by superoxide radicals. Brain Res677: 345–347
41.
House R V, Thomas P T, Bhargava H N (1994) Comparison of immune functional parameters following in vitro exposure to natural and synthetic amphetamines. Immunopharmacol Immunotoxicol16: 1–21
42.
Ishikawa T, Yamamoto M (1979) Involvement of the cholinergic mechanism in depression of the caudate spindle. Jpn J Pharmacol29: 399–403
43.
Ketzler S, Weisl S, Haug H, Budka H (1990) Loss of neurons in the frontal cortex in AIDS brains. Acta Neuropathol80: 1799–1808
44.
Kipke M D, O'Connor S, Palmer R, MacKenzie R G (1995) Street youth in Los Angeles. Profile of a group at high risk for human immunodeficiency virus infection. Arch Pediatr Adolesc Med149: 513–519
45.
Kiyomasu T, Miyazawa T, Furuya T, Shibata R, Sakai H, Sakuragi J, Fukasawa M, Maki N, Hasegawa A, Mikami T, et al. (1991) Identification of feline immunodeficiency virus rev gene activity. J Virol65: 4539–4542
46.
Koka P, He K, Zack J A, Kitchen S, Peacock W, Fried I, Tran T, Yashar S S, Merrill J E (1995) Human immunodeficiency virus 1 envelope proteins induce interleukin 1, tumor necrosis factor alpha, and nitric oxide in glial cultures derived from fetal, neonatal, and adult human brain. J Exp Med182: 941–951
47.
Kong L Y, Wilson B C, McMillian M K, Bing G, Hudson P M, Hong J S (1996) The effects of the HIV-1 envelope protein gp120 on the production of nitric oxide and proinflammatory cytokines in mixed glial cell cultures. Cell Immunol172: 77–83
48.
Koutsilieri E, Gotz M E, Sopper S, Sauer U, Demuth M, ter Meulen V, Riederer P (1997) Regulation of glutathione and cell toxicity following exposure to neurotropic substances and human immunodeficiency virus-1 in vitro. J Neurovirol3: 342–349
49.
Kure K, Weidenheim K M, Lyman W D, Dickson D W (1990) Morphology and distribution of HIV-1 gp41-positive microglia in subacute AIDS encephalitis. Pattern of involvement resembling a multisystem degeneration. Acta Neuropathol (Berl)80: 393–400
50.
Lannuzel A, Lledo P M, Lamghitnia H O, Vincent J D, Tardieu M (1995) HIV-1 envelope proteins gp120 and gp160 potentiate NMDA-induced [Ca2+]i increase, alter [Ca2+]i homeostasis and induce neurotoxicity in human embryonic neurons. Eur J Neurosci7: 2285–2293
51.
Lipton S A (1994) Neuronal injury associated with HIV-1 and potential treatment with calcium-channel and NMDA antagonists. Dev Neurosci16: 145–151
52.
Lipton S A (1996) Similarity of neuronal cell injury and death in AIDS dementia and focal cerebral ischemia: potential treatment with NMDA open-channel blockers and nitric oxiderelated species. Brain Pathol6: 507–517
53.
Lipton S A, Sucher N J, Kaiser P K, Dreyer E B (1991) Synergistic effects of HIV coat protein and NMDA receptor-mediated neurotoxicity. Neuron7: 111–118
54.
Lipton S A, Yeh M, Dreyer E B (1994) Update on current models of HIV-related neuronal injury: platelet-activating factor, arachidonic acid and nitric oxide. Adv Neuroimmunol4: 181–188
55.
Lo T M, Fallert C J, Piser T M, Thayer S A (1992) HIV-1 envelope protein evokes intracellular calcium oscillations in rat hippocampal neurons. Brain Res594: 189–196
56.
Maeda H, Maki S (1986) Dopaminergic facilitation of recovery from amygdaloid lesions which affect hypothalamic defensive attack in cats. Brain Res363: 135–140
57.
Maeda H, Maki S (1987) Dopamine agonists produce functional recovery from septal lesions which affect hypothalamic defensive attack in cats. Brain Res407: 381–385
58.
Maeda H, Sato T, Maki S (1985) Effects of dopamine agonists on hypothalamic defensive attack in cats. Physiol Behav35: 89–92
59.
Malberg J E, Sabol K E, Seiden L S (1996) Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. J Pharmacol Exp Ther278: 258–267
60.
Marshall J F, O'Dell S J, Weihmuller F B (1993) Dopamine– glutamate interactions in methamphetamine-induced neurotoxicity. J Neural Transm Gen Sect91: 241–254
61.
Masliah E, Ge N, Achim C L, Hansen L A, Wiley C A (1992a) Selective neuronal vulnerability in HIV encephalitis. J Neuropathol Exp Neurol51: 585–593
62.
Masliah E, Ge N, Morey M, DeTeresa R, Terry R D, Wiley C A (1992b) Cortical dendritic pathology in human immunodeficiency virus encephalitis. Lab Invest66: 285–291
63.
Masliah E, Heaton R K, Marcotte T D, Ellis R J, Wiley C A, Mallory M, Achim C L, McCutchan J A, Nelson J A, Atkinson J H, Grant I, Group H (1997) Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. Ann Neurol42: 963–972
64.
Meeker R B, Thiede B A, Hall C, English R, Tompkins M (1997) Cortical cell loss in asymptomatic cats experimentally infected with feline immunodeficiency virus. AIDS Res Hum Retrovir13: 1131–1140
65.
Miller D B, O'Callaghan J P (1994) Environment-, drug- and stressinduced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6 J mouse. J Pharmacol Exp Ther270: 752–760
66.
Miyazawa T, Fukasawa M, Hasegawa A, Maki N, Ikuta K, Takahashi E, Hayami M, Mikami T (1991) Molecular cloning of a novel isolate of feline immunodeficiency virus biologically and genetically different from the original US isolate. J Virol65: 1572–1577
67.
Molitor F, Truax S R, Ruiz J D, Sun R K (1998) Association of methamphetamine use during sex with risky sexual behaviors and HIV infection among non-injection drug users. West J Med168: 93–97
68.
Molliver M E, Berger U V, Mamounas L A, Molliver D C, O'Hearn E, Wilson M A (1990) Neurotoxicity of MDMA and related compounds: anatomic studies. Ann NY Acad Sci600: 649–661, 661–644
69.
Muller W E G, Schroder H C, Ushijima H, Dapper J, Bormann J (1992) Gp120 of HIV1 induces apoptosis in rat cortical cell cultures: prevention by memantine. Eur J Pharmacol Mol Pharmacol226: 209–214
70.
North T W, North G L, Pedersen N C (1989) Feline immunodeficiency virus, a model for reverse transcriptasetargeted chemotherapy for acquired immune deficiency syndrome. Antimicrob Agents Chemother33: 915–919
71.
North T W, Cronn R C, Remington K M, Tandberg R T (1990a) Direct comparisons of inhibitor sensitivities of reverse transcriptases from feline and human immunodeficiency viruses. Br Vet J146: 468–475
72.
North T W, Cronn R C, Remington K M, Tandberg R T, Judd R C (1990b) Characterization of reverse transcriptase from feline immunodeficiency virus. J Biol Chem265: 5121–5128
73.
Nunez-Iglesias M J, Castro-Bolano C, Losada C, Pereiro-Raposo M D, Riveiro P, Sanchez-Sebio P, Mayan-Santos J M, Rey-Mendez M, Freire-Garabal M (1996) Effects of amphetamine on cell mediated immune response in mice. Life Sci58: 29–33
74.
Olmsted R A, Hirsch V M, Purcell R H, Johnson P R (1989) Nucleotide sequence analysis of feline immunodeficiency virus: genome organization and relationship to other lentiviruses. Proc Natl Acad Sci USA86: 8088–8092
75.
Pardo J, Marcos A, Bhathal H, Castro M, Varea de Seijas E (1998) Chorea as a form of presentation of human immunodeficiency virus-associated dementia complex. Neurology50: 568–569
76.
Perovic S, Schleger C, Pergande G, Iskric S, Ushijima H, Rytik P, Muller W E (1994) The triaminopyridine flupirtine prevents cell death in rat cortical cells induced by N-methyl-D-aspartate and gp120 of HIV-1. Eur J Pharmacol288: 27–33
77.
Peters A, Davies T, Richardson A (1997) Increasing popularity of injection as the route of administration of amphetamine in Edinburgh. Drug Alcohol Dep48: 227–234
78.
Phillips T R, Talbott R L, Lamont C, Muir S, Lovelace K, Elder J H (1990) Comparison of two host cell range variants of feline immunodeficiency virus. J Virol64: 4605–4613
79.
Phillips T R, Lamont C, Konings D A M, Shacklett B L, Hamson C A, Luciw P A, Elder J H (1992) Identification of the rev transactivation and rev-responsive elements of feline immunodeficiency virus. J Virol66: 5464–5471
80.
Podell M, March P A, Buck W R, Mathes L E (2000a) The feline model of neuroAIDS: understanding the progression towards AIDS dementia. J Psychopharmacol14: 000–000
81.
Poli A, Abramo F, Di Iorio C, Cantile C, Carli M A, Pollera C, Vago L, Tosoni A, Costanzi G (1997) Neuropathology in cats experimentally infected with feline immunodeficiency virus: a morphological, immunocytochemical and morphometric study. J Neurovirol3: 361–368
82.
Power C, Kong P A, Crawford T O, Wesselingh S, Glass J D, McArthur J C, Trapp B D (1993) Cerebral white matter changes in acquired immunodeficiency syndrome dementia: alterations of the blood–brain barrier. Ann Neurol34: 339–350
83.
Power C, Moench T, Peeling J, Kong P A, Langelier T (1997) Feline immunodeficiency virus causes increased glutamate levels and neuronal loss in brain. Neuroscience77: 1175–1185
84.
Remington K M, Chesebro B, Wehrly K, Pedersen N C, North T W (1991) Mutants of feline immunodeficiency virus resistant to 3[.minute]-azido-3[.minute]-deoxythymidine. J Virol65: 308–312
85.
Ricaurte G A, McCann U D (1992) Neurotoxic amphetamine analogues: effects in monkeys and implications for humans. Ann NY Acad Sci648: 371–382
86.
Ricaurte G A, Guillery R W, Seiden L S, Schuster C R, Moore R Y (1982) Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res235: 93–103
87.
Ricaurte G A, Seiden L S, Schuster C R (1984) Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers. Brain Res303: 359–364
88.
Rotheram-Borus M J, Cajetan Luna G, Marotta T, Kelly H (1994) Going nowhere fast: methamphetamine use and HIV infection. NIDA Res Monogr143: 155–182
89.
Rottenberg D A, Sidtis J J, Strother S C, Schaper K A, Anderson J R, Nelson M J, Price R W (1996) Abnormal cerebral glucose metabolism in HIV-1 seropositive subjects with and without dementia. J Nucl Med37: 1133–1141
90.
Ryan L, Linder J, Martone M, Groves P (1990) Histological and ultrastructural evedencethat D-amphetamine causes degeneration in neostriatum and frontal cortex of rats. Brain Res518: 67–77
91.
Sahakian B J, Elliott R, Low N, Mehta M, Clark R T, Pozniak A L (1995) Neuropsychological deficits in tests of executive function in asymptomatic and symptomatic HIV-1 seropositive men. Psychol Med25: 1233–1246
92.
Sato M (1983) Long-lasting hypersensitivity to methamphetamine following amygdaloid kindling in cats: the relationship between limbic epilepsy and the psychotic state. Biol Psychiatry18: 525–536
93.
Sato M, Tomoda T, Hikasa N, Otsuki S (1980) Inhibition of amygdaloid kindling by chronic pretreatment with cocaine or methamphetamine. Epilepsia21: 497–507
94.
Savio T, Levi G (1993) Neurotoxicity of HIV coat protein gp120, NMDA receptors, and protein kinase C: a study with rat cerebellar granule cell cultures. J Neurosci Res34: 265–272
95.
Sindou P, Couratier P, Esclaire F, Yardin C, Bousseau A, Hugon J (1994) Prevention of HIV coat protein (gp120) toxicity in cortical cell cultures by riluzole. J Neurol Sci126: 133–137
96.
Sonsalla P K, Nicklas W J, Heikkila R E (1989) Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science243: 398–400
97.
Sparger E E, Shacklett B L, Renshaw G L, Barry P A, Pedersen N C, Elder J H, Luciw P A (1992) Regulation of gene expression directed by the long terminal repeat of the feline immunodeficiency virus. Virology187: 165–177
98.
Stefano G B, Smith E M, Paemen L R, Hughes Jr. T K (1993) HIV gp120 associated neurological deficits: a potential role for nitric oxide and other signal molecules. Adv Neuroimmunol3: 47–57
99.
Stephans S, Yamamoto B (1994) methamphetamine-induced neurotoxicity: Roles for glutamate and dopamine eflux. Synapse17: 203–209
100.
Sudilovsky A, Nelson L, Ellinwood E H Jr (1974) Amphetamine dyskinesia: a direct observational study in cats. In Singh J M, Lal H (ed.), Drug addiction, vol. 4. New aspects of analytical and clinical toxicology. New York, Stratton, pp. 17–37
101.
Talbott R L, Sparger E E, Lovelace K M, Fitch W M, Pedersen N C, Luciw P A, Elder J H (1989) Nucleotide sequence and genomic organization of feline immunodeficiency virus. Proc Natl Acad Sci USA86: 5743–5747
102.
Toggas S M, Masliah E, Rockenstein E M, Rall G F, Abraham C R, Mucke L (1994) Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice [see comments]. Nature367: 188–193
103.
Toggas S M, Masliah E, Mucke L (1996) Prevention of HIV-1 gp120-induced neuronal damage in the central nervous system of transgenic mice by the NMDA receptor antagonist memantine. Brain Res706: 303–307
104.
Truckenmiller M E, Kulaga H, Coggiano M, Wyatt R, Snyder S H, Sweetnam P M (1993) Human cortical neuronal cell line: a model for HIV-1 infection in an immature neuronal system. Aids Res Hum Retrovir9: 445–453
105.
Wiley C, Masliah E, Morey M, Lemere C, DeTeresa R, Grafe M, Hansen L, Terry R (1991a) Neocortical damage during HIV infection. Ann Neurol29: 651–657
106.
Wiley C A, Masliah E, Morey M, Lemere C, DeTeresa R, Grafe M, Hansen L, Terry R (1991b) Neocortical damage during HIV infection. Ann Neurol29: 651–657
107.
Woods S W, O'Malley S S, Martini B L, McDougle C J, Price L H, Krystal J H, Hoffer P B, Kosten T R (1991) SPECT regional cerebral blood flow and neuropsychological testing in nondemented HIV-positive drug abusers: preliminary results. Prog Neuropsychopharmacol Biol Psychiatry15: 649–662
108.
Woolverton W L, Ricaurte G A, Forno L S, Seiden L S (1989) Longterm effects of chronic methamphetamine administration in rhesus monkeys. Brain Res486: 73–78
109.
Yeung M C, Pulliam L, Lau A S (1995) The HIV envelope protein gp120 is toxic to human brain-cell cultures through the induction of interleukin-6 and tumor necrosis factor-alpha. AIDS9: 137–143
110.
Yu N, Billaud J N, Phillips T R (1998) Effects of feline immunodeficiency virus on astrocyte glutamate uptake: implications for lentivirus-induced central nervous system diseases. Proc Natl Acad Sci USA95: 2624–2629
111.
Zenger E, Collisson E W, Barhoumi R, Burghardt R C, Danave I R, Tiffany-Castiglioni E (1995) Laser cytometric analysis of FIV-induced injury in astroglia. Glia13: 92–100
